Approximately 20% of patients with AML have an IDH mutation1,2
Mutated IDH leads to a block on myeloid differentiation and an accumulation of myeloblasts: the hallmark of AML1,3
Greater than 99% of patients with AML have at least 1 gene mutation4*
Molecular profiling is important to identify gene mutations associated with AML5
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) suggest molecular profiling in patients with relapsed/refractory AML to assist with selection of appropriate clinical trials6
Your pathologist can help you determine the best method for molecular profiling in AML
Clinical trials are available for patients with newly diagnosed or relapsed/refractory AML who harbor IDH mutations7
Based on a recent analysis of 200 patients with de novo AML.
AML, acute myeloid leukemia; IDH, isocitrate dehydrogenase.